Wegovy® 7.2 mg – what do we know so far?
Novo Nordisk has recently announced a higher maintenance dose of semaglutide (Wegovy®) at 7.2 mg once weekly, representing a significant increase from the current standard maximum dose of 2.4 mg. Early clinical trial data suggest that this higher dose may lead to greater weight loss, with average total body weight loss approaching 20–21%, compared with around 14–15% seen with the 2.4 mg dose in earlier STEP trials. While these results are encouraging, it is important to emphasise that this dosing strategy is new, real-world experience is limited, and we are still learning how best it fits into established treatment pathways.
As with all GLP-1 receptor agonists, higher doses are associated with more frequent and sometimes more intense side-effects. These are predominantly gastrointestinal and include nausea, vomiting, diarrhoea, constipation, abdominal pain and reflux. At the 7.2 mg dose there appears to be a higher incidence of hair thinning, altered skin sensation, fatigue and dizziness, as well as a greater risk of dehydration if vomiting or diarrhoea occur. For this reason, careful patient selection and close monitoring will be essential.
We will update our patients as further guidance, real-world data and clinical experience become available.
Who might the 7.2 mg dose be for?
In our view, the most logical group for consideration of Wegovy® 7.2 mg are patients who:
Have been established on 2.4 mg for a sustained period
Have tolerated this dose without significant or limiting side-effects
Have experienced a weight-loss plateau
Have achieved less than ~20% total body weight loss, which is the level seen on average in trials of the higher dose
Conversely, if a patient has already achieved around 20% weight loss (or more) on 2.4 mg or a lower dose, there is little rationale for escalating to a higher dose, as the potential increase in side-effects is unlikely to be offset by meaningful additional benefit.
Who is eligible?
Based on current guidance and the patient information released so far, eligibility for the 7.2 mg dose appears to be limited to:
Adults with a starting BMI ≥30 kg/m²
Patients who are already established on 2.4 mg
Those who have not experienced marked or problematic side-effects at the standard maintenance dose
As with all obesity treatments, escalation should only occur as part of a structured, medically supervised programme, with ongoing review of benefit, tolerability and safety.
What about cost?
At present, there is no dedicated 7.2 mg Wegovy® pen. Instead, the higher dose is administered as three separate 2.4 mg injections on the same day, given at different sites at least 5 cm apart. This means that, in practical terms, a patient would use three-quarters of a 2.4 mg pen per week.
How this will ultimately be priced in the UK is not yet clear. Logically, the medication cost alone should be substantially higher than a single 2.4 mg weekly dose, given the increased amount of drug used. Some pharmacies are already advertising provisional prices for 7.2 mg that appear only marginally higher than the standard dose, which does not currently make commercial sense and may reflect assumptions rather than confirmed supply pricing.
We believe it is important to be transparent: until supply chains, prescribing guidance and pharmacy pricing are fully clarified, we cannot give patients an accurate cost. As soon as we are able to do so, we will update all eligible patients directly.
In summary
The introduction of Wegovy® 7.2 mg is an interesting and potentially valuable development in medical weight management. Trial data suggest it may help some patients achieve greater weight loss than the current 2.4 mg dose, but this comes with a higher burden of side-effects, and many practical questions remain unanswered.
At this stage, we see it as a selective option for patients who have tolerated 2.4 mg well but have stalled short of the weight-loss levels seen in higher-dose trials. It is not a universal next step, nor is it necessary for patients already doing well on lower doses.
As evidence evolves and UK prescribing and pricing become clearer, we will continue to review where this dose fits within our treatment pathways — and we will keep our patients fully informed every step of the way.
